The American Healthcare Conundrum

Hospital pricing and markups

• Author’s pipeline on CMS HCRIS data (3,193 hospitals, FY2023) finds very high markups on cost: median 2.6× overall, ~3.96× for nonprofits vs ~2.4× for for‑profit and ~1.9× for government hospitals.
• Some argue this undermines the “cross‑subsidizing Medicare” narrative and instead reflects market power and consolidation; others still see cross‑subsidy as real, especially for Medicaid and underpaid services.
• Huge variation in cost‑to‑charge ratios even among similar hospitals suggests arbitrary or market‑power‑driven pricing, not cost.

Medicare vs commercial insurers

• Several commenters say Medicare is among the best, most reliable payers, with transparent formulas and lump‑sum or value‑based payments; some private contracts even peg to a % of Medicare.
• Others insist Medicare and especially Medicaid underpay, forcing providers to recoup from commercial plans; some hospitals cap Medicare/Medicaid patients or rely on portfolio effects.
• There’s disagreement over how much of US overpricing is due to Medicare’s monopsony vs private insurer weakness in local hospital markets.

ACA, medical loss ratios, and insurer incentives

• One camp claims ACA’s 80–85% minimum medical loss ratio (MLR) makes insurers want higher total spending: 20% of a bigger pie.
• Critics counter that margins are low (single‑digit %), markets are somewhat competitive, and much large‑employer coverage is self‑funded so the “spend more to earn more” story is oversimplified.
• Vertical integration (insurer + PBM + clinics/pharmacies) lets conglomerates count internal transfers as “medical spend,” potentially gaming MLR.

PBMs and drug pricing

• PBMs are widely portrayed as a major distortion: spread pricing, rebate games, steering to owned pharmacies, and markups that make cash/discount‑card prices lower than insured prices.
• Some argue high US drug prices subsidize global pharma R&D; others see that as industry propaganda and emphasize marketing and lobbying.

Administrative overhead and complexity

• Administrative/billing overhead is described as 15–30% of US health spending, far above peers, with physicians losing significant time to billing.
• Medicare’s low visible admin overhead is said to be partially offloaded to providers (e.g., complex cost reports and documentation).

Provider pay, workforce, and malpractice

• US doctors and nurses earn much more than in many countries; some see deliberate supply constraints (med school slots, residencies, AMA influence) and high malpractice costs as drivers.
• Others note physician income is <10% of total spend, so high pay is “a factor but not the main one.”

International comparisons and lifestyle

• Japan and European systems are repeatedly contrasted: lower per‑capita and %‑GDP spending with equal or better outcomes, though commenters note huge lifestyle differences (diet, obesity, transit use) and demographic structure.
• Some argue US outcomes look better if you adjust for income or focus on specific subpopulations; others highlight that almost all rich countries outperform the US on cost‑for‑outcome.

Structure, politics, and reform ideas

• Widely shared themes: misaligned incentives, regulatory capture, lobbying (~$750M/year cited), and fragmentation across payers.
• Proposed directions include single‑payer or public option, all‑payer rate‑setting (Maryland as example), stronger price transparency, decoupling insurance from employment, tort reform, and tackling food/agriculture drivers of metabolic disease.
• There is broad agreement the system is deeply broken; disagreement centers on whether insurers, providers, regulation, or broader political economy are primary culprits, and on how radical reforms can be implemented without collapse.